Skye Bioscience (SKYE) Price to Earnings (2015 - 2026)

Skye Bioscience (SKYE) has reported Price to Earnings for 12 consecutive years, with 0.28 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Earnings rose 76.1% year-over-year to 0.28 in Q2 2026; TTM through Jun 2026 was 0.06, a 87.72% increase from a year earlier, with the FY2025 full-year figure at 0.06, up 86.43% from the prior year.
• Price to Earnings was 0.28 for Q2 2026 at Skye Bioscience, down from 0.22 in the prior quarter.
• Over five years, Price to Earnings peaked at 0.11 in Q4 2022 and troughed at 10.93 in Q1 2024.
• A 5-year average of 1.66 and a median of 0.67 in 2022 frame the typical range for Price to Earnings.
• Across the five-year window, Price to Earnings plunged 2913.48% in 2024 and soared 93.51% in 2025, its largest moves.
• Over 5 years, Price to Earnings stood at 0.11 in 2022, then sank by 380.03% to 0.54 in 2023, then sank by 108.6% to 1.12 in 2024, then surged by 80.73% to 0.22 in 2025, then retreated by 29.69% to 0.28 in 2026.
• The last three Price to Earnings figures came in at 0.28 (Q2 2026), 0.22 (Q1 2026), and 0.22 (Q4 2025), per Business Quant data.